Belite Bio (BLTE) News Today $86.90 -0.81 (-0.92%) As of 10:07 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BLTE Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Belite Bio (NASDAQ:BLTE) Trading Up 6.7% - Should You Buy?October 17 at 2:40 PM | marketbeat.comBelite Bio (NASDAQ:BLTE) Sets New 12-Month High - Still a Buy?October 17 at 5:32 AM | marketbeat.comLeerink bullish on Belite Bio, says tinlarebant news another positive data pointOctober 16, 2025 | msn.comBelite Bio to Participate in the 2025 Maxim Growth SummitOctober 16, 2025 | markets.businessinsider.comBelite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with TinlarebantOctober 15, 2025 | globenewswire.comBelite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Average Recommendation of "Moderate Buy" by BrokeragesOctober 13, 2025 | marketbeat.comBelite Bio (NASDAQ:BLTE) Given Sell (D-) Rating at Weiss RatingsOctober 9, 2025 | marketbeat.com3 Lesser-Known Healthcare Names With Major Upside in Store (BLTE)These are three healthcare stocks offering a compelling combination of secure business, strong fundamentals, and growth opportunity.October 2, 2025 | marketbeat.comBelite Bio (NASDAQ:BLTE) Sees Strong Trading Volume - Here's WhySeptember 24, 2025 | marketbeat.comBelite Bio (NASDAQ:BLTE) Upgraded to "Hold" at Wall Street ZenSeptember 20, 2025 | marketbeat.comBelite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Average Rating of "Moderate Buy" by AnalystsSeptember 19, 2025 | marketbeat.comBelite Bio (NASDAQ:BLTE) Raised to "Hold" at Zacks ResearchSeptember 19, 2025 | marketbeat.comBelite Bio (NASDAQ:BLTE) Sees Strong Trading Volume - Time to Buy?September 18, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for Belite Bio Q3 Earnings?September 18, 2025 | marketbeat.comBelite Bio (NASDAQ:BLTE) Price Target Lowered to $98.00 at HC WainwrightSeptember 16, 2025 | marketbeat.comBelite Bio price target lowered to $98 from $100 at H.C. WainwrightSeptember 15, 2025 | msn.comBelite Bio (BLTE) Completes Phase 3 DRAGON Trial Enrollment For Stargardt TreatmentSeptember 13, 2025 | uk.finance.yahoo.comBelite Bio completes Phase 3 DRAGON trial of TinlarebantSeptember 12, 2025 | msn.comBelite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt DiseaseSeptember 12, 2025 | globenewswire.comBelite Bio (NASDAQ:BLTE) Shares Gap Up - Should You Buy?September 10, 2025 | marketbeat.comBelite Bio Secures $125 Million in PIPE Financing with Potential for MoreSeptember 9, 2025 | msn.comBelite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare InvestorsSeptember 8, 2025 | globenewswire.comAlyeska Investment Group L.P. Buys Shares of 83,623 Belite Bio, Inc. Sponsored ADR $BLTESeptember 8, 2025 | marketbeat.comBelite Bio (NASDAQ:BLTE) Shares Down 2.3% - Here's What HappenedSeptember 3, 2025 | marketbeat.comHC Wainwright Has Negative Outlook of Belite Bio Q3 EarningsAugust 16, 2025 | marketbeat.comQ3 EPS Estimates for Belite Bio Decreased by Leerink PartnrsAugust 16, 2025 | marketbeat.comBelite Bio FY2029 EPS Forecast Decreased by Leerink PartnrsAugust 15, 2025 | marketbeat.comBelite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual ConferenceAugust 13, 2025 | theglobeandmail.comBelite Bio’s Earnings Call: Progress Amid ChallengesAugust 13, 2025 | msn.comBelite Bio (NASDAQ:BLTE) Posts Quarterly Earnings Results, Misses Estimates By $0.08 EPSAugust 12, 2025 | marketbeat.comBelite Bio, Inc (BLTE) Q2 2025 Earnings Call TranscriptAugust 11, 2025 | seekingalpha.comBelite Bio, Inc 2025 Q2 - Results - Earnings Call PresentationAugust 11, 2025 | seekingalpha.comBelite Bio, Inc: Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate UpdateAugust 11, 2025 | finanznachrichten.deBelite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate UpdateAugust 11, 2025 | globenewswire.com1BLTE : Belite Bio's Earnings OutlookAugust 8, 2025 | benzinga.comBelite Bio Announces Registered Direct Offering of $15 MillionAugust 7, 2025 | globenewswire.comBelite Bio (NASDAQ:BLTE) Shares Up 0.3% - What's Next?August 2, 2025 | marketbeat.comBelite Bio (BLTE) Expected to Announce Earnings on FridayAugust 1, 2025 | marketbeat.comA Look At The Intrinsic Value Of Belite Bio, Inc (NASDAQ:BLTE)July 27, 2025 | finance.yahoo.comBelite Bio to Participate in the BTIG Virtual Biotechnology ConferenceJuly 25, 2025 | tmcnet.comBelite Bio Inc ADR News (BLTE) - Investing.comJuly 23, 2025 | investing.comBelite Bio (NASDAQ:BLTE) Sees Large Volume Increase - Should You Buy?July 15, 2025 | marketbeat.comBelite Bio (NASDAQ:BLTE) Shares Gap Down - What's Next?July 10, 2025 | marketbeat.comLeerink Partnrs Has Weak Estimate for Belite Bio Q2 EarningsJuly 10, 2025 | marketbeat.comLeerink Partnrs Comments on Belite Bio FY2029 EarningsJuly 9, 2025 | marketbeat.comBelite Bio (NASDAQ:BLTE) Sees Large Volume Increase - Here's What HappenedJuly 7, 2025 | marketbeat.comBelite Bio's (BLTE) "Buy" Rating Reaffirmed at HC WainwrightJuly 3, 2025 | marketbeat.comBelite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic AtrophyJuly 2, 2025 | globenewswire.comBelite Bio (NASDAQ:BLTE) Sees Large Volume Increase - Time to Buy?June 30, 2025 | marketbeat.comBelite Bio, Inc (NASDAQ:BLTE) Sees Large Growth in Short InterestJune 17, 2025 | marketbeat.com Get Belite Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BLTE Media Mentions By Week BLTE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BLTE News Sentiment▼0.600.49▲Average Medical News Sentiment BLTE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BLTE Articles This Week▼53▲BLTE Articles Average Week Get the Latest News and Ratings for BLTE and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Belite Bio and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies ELAN News VRNA News RVMD News ABVX News RNA News CYTK News MRUS News RYTM News CRSP News GRFS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BLTE) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersThis dark force is about to change everythingSomething unusual is unfolding inside the Republican Party — from Marjorie Taylor Greene breaking ranks to Ted...Porter & Company | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredBlackRock’s Shocking Crypto MoveBlackRock, Fidelity, and JPMorgan have quietly shifted billions out of Bitcoin and into a single emerging cryp...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Belite Bio, Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Belite Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
